Novavax, Inc. [NASDAQ: NVAX] traded at a high on Monday, posting a 1.34 gain after which it closed the day’ session at $12.06.
The results of the trading session contributed to over 5517505 shares changing hands. Over the past one week, the price volatility of Novavax, Inc. stands at 6.85% while the volatility over the past one month is 8.69%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for NVAX stock reached $1.69 billion, with 139.51 million shares outstanding and 133.33 million shares in the current float. Compared to the average trading volume of 16.06M shares, NVAX reached a trading volume of 5517505 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Novavax, Inc. [NVAX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $22.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Novavax, Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 10, 2024. While these analysts kept the previous recommendation, BofA Securities dropped their target price from $4 to $12. The new note on the price target was released on May 10, 2024, representing the official price target for Novavax, Inc. stock. Previously, the target price had yet another raise to $15, while B. Riley Securities analysts kept a Buy rating on NVAX stock. On April 20, 2023, analysts decreased their price target for NVAX shares from 55 to 10.
The Average True Range (ATR) for Novavax, Inc. is set at 1.21, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 1.70.
How has NVAX stock performed recently?
Novavax, Inc. [NVAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.74. With this latest performance, NVAX shares dropped by -42.49% in over the last four-week period, additionally plugging by 133.72% over the last 6 months – not to mention a rise of 70.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 40.34, with the RSI for the last a single of trading hit 31.41, and the three-weeks RSI is set at 46.25 for Novavax, Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 12.39, while it was recorded at 12.44 for the last single week of trading, and 7.11 for the last 200 days.
Novavax, Inc. [NVAX]: Deeper insight into the fundamentals
Novavax, Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.88 and a Current Ratio set at 0.90.
Earnings analysis for Novavax, Inc. [NVAX]
With the latest financial reports released by the company, Novavax, Inc. posted 0.58/share EPS, while the average EPS was predicted by analysts to be reported at -1.39/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 141.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax, Inc. go to 37.90%.
Insider trade positions for Novavax, Inc. [NVAX]
The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in NVAX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in NVAX stock with ownership which is approximately 5.1238%.
